The restructuring was the first major move by Novo Nordisks new President and CEO Mike Doustdar, who took over the helm at the company in early August (August 2025), succeeding then CEO and President Lars Fruergaard Jrgensen, who had announced in May (May 2025) that he would be stepping down.
[13] A 2021 meta-analysis found that over 1 year of clinical use, tirzepatide was superior to dulaglutide, semaglutide, insulin degludec, and insulin glargine in improving blood sugar control and reducing body weight
glutathione peroxidase 4 (phospholipid hydroperoxidase)
Because oxidative stress increases due to direct sunlight, pollution, and outdoor exposure, taking glutathione in the morning provides powerful antioxidant protection throughout the day, helping the skin defend itself against UV-triggered pigmentation and cellular damage